Hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and molecular targeted therapies for advanced infiltrative hepatocellular carcinoma: a single-center experience

Hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and molecular targeted therapies for advanced infiltrative hepatocellular carcinoma: a single-center experience

BackgroundInfiltrative hepatocellular carcinoma (HCC) remains a therapeutic challenge due to its aggressive course and poor prognosis. Hepatic arterial infusion chemotherapy (HAIC) plus immune checkpoint inhibitors (ICIs) and molecular targeted therapies (MTTs) has shown early promise for advanced H...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zizhuo Wang, Songlin Song, Lijie Zhang, Tingting Yang, Wei Yao, Bin Liang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Immunology
Subjects:	infiltrative hepatocellular carcinoma hepatocellular carcinoma hepatic arterial infusion immunotherapy molecular targeted therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1474442/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Successful treatment of tumor lysis syndrome associated with hepatic artery infusion chemotherapy in a patient with hepatocellular carcinoma: a case report
by: Miao Li, et al.
Published: (2024-12-01)

Peritumor tertiary lymphoid structures are associated with infiltrating neutrophils and inferior prognosis in hepatocellular carcinoma
by: Tianchen Zhang, et al.
Published: (2023-02-01)

Improved survival with second-line hepatic arterial infusion chemotherapy after atezolizumab-bevacizumab failure in hepatocellular carcinoma
by: Ji Yeon Lee, et al.
Published: (2024-12-01)

AI-based tumor-infiltrating lymphocyte scoring system for assessing HCC prognosis in patients undergoing liver resection
by: Zhiyang Chen, et al.
Published: (2025-02-01)

Establishment of prognostic risk model related to disulfidptosis and immune infiltration in hepatocellular carcinoma
by: Zhe Xu, et al.
Published: (2024-12-01)

Clinical Outcomes of Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab for Treating Hepatocellular Carcinoma and Type IV Portal Vein Tumor Thrombus
by: Li X, et al.
Published: (2025-01-01)

TMEM101 expression and its impact on immune cell infiltration and prognosis in hepatocellular carcinoma
by: Lingyun Kuang, et al.
Published: (2024-12-01)

Tumor Intrinsic Immunogenicity Suppressor SETDB1 Worsens the Prognosis of Patients with Hepatocellular Carcinoma
by: Chang-Qing Yin, et al.
Published: (2024-12-01)

Nanoparticles and their application in the diagnosis of hepatocellular carcinoma
by: Li Xinxin, et al.
Published: (2024-11-01)

Hepatic arterial infusion chemotherapy combined with systemic therapy sequentially or simultaneously for advanced hepatocellular carcinoma
by: Yu-zhe Cao, et al.
Published: (2024-11-01)

Identification of ribosomal protein S21 as a potential prognostic and immunotherapy biomarker for hepatocellular carcinoma
by: Junhan Pan, et al.
Published: (2025-01-01)

FLT3 is associated with dendritic cell infiltration, tertiary lymphoid structure construction, and predict response to checkpoint inhibitors immunotherapy in solid cancers
by: Yongchang Tang, et al.
Published: (2025-01-01)

T cell receptor repertoire profiling predicts the prognosis of HBV‐associated hepatocellular carcinoma
by: Kai‐Rong Lin, et al.
Published: (2018-08-01)

Single‐Nucleus and Spatial Transcriptome Profiling Delineates the Multicellular Ecosystem in Hepatocellular Carcinoma After Hepatic Arterial Infusion Chemotherapy
by: YeXing Huang, et al.
Published: (2025-02-01)

Correspondence to editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma”
by: Su Bin Lim, et al.
Published: (2024-10-01)

Bioinformatics Analysis Reveals CDK1 and DLGAP5 as Key Modulators of Tumor Immune Cell Infiltration in Hepatocellular Carcinoma
by: Li J, et al.
Published: (2024-11-01)

The role of histone lactylation genes in hepatocellular carcinoma prognostic models and their immune cell infiltration features: a comprehensive analysis of single-cell, spatial transcriptome, Mendelian randomization and experiment
by: Shanjie Luan
Published: (2025-01-01)

Myeloid response evaluated by noninvasive CT imaging predicts post-surgical survival and immune checkpoint therapy benefits in patients with hepatocellular carcinoma
by: Kangqiang Peng, et al.
Published: (2024-12-01)

Identification of pyroptosis-associated miRNAs in the immunoscape and prognosis of hepatocellular carcinoma
by: Yuting Zheng, et al.
Published: (2024-12-01)

Enhanced antitumor activity of combined hepatic arterial infusion chemotherapy with Lenvatinib and PD-1 inhibitors in unresectable hepatocellular carcinoma: a meta-analysis
by: Lingling Zhao, et al.
Published: (2025-02-01)

Preoperative assessment of liver regeneration using T1 mapping and the functional liver imaging score derived from Gd-EOB-DTPA-enhanced magnetic resonance for patient with hepatocellular carcinoma after hepatectomy
by: Qian Li, et al.
Published: (2025-01-01)

Study of TRAF3IP3 for prognosis and immune infiltration in hepatocellular carcinoma
by: Xing Wang, et al.
Published: (2024-12-01)

Bibliometric analysis of immune checkpoint inhibitors to treat hepatocellular carcinoma in patients with liver transplantation
by: Yanjiao Ou, et al.
Published: (2025-01-01)

Hepatocellular carcinoma in a sheep
by: Zabid Yener, et al.

CGRRF1 as a potential diagnostic and prognostic biomarker for hepatocellular carcinoma
by: Yao Rong, et al.
Published: (2025-01-01)

Conversion therapy for advanced biphenotypic hepatocellular carcinoma: A case report
by: Yu Zhang, et al.
Published: (2025-01-01)

Metabolic dysfunction-associated fatty liver disease related hepatocellular carcinoma in China: An increasing problem: Letter to the edior on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis”
by: Xiangyu Wu, et al.
Published: (2024-10-01)

Nanoparticles and the treatment of hepatocellular carcinoma
by: Zhang Ziyu, et al.
Published: (2024-12-01)

High expression of MRPL52 can be used as a prognostic marker of hepatocellular carcinoma and is related to immune infiltration
by: Nan HUANG, et al.
Published: (2021-12-01)

A new prognostic model for predicting overall survival and progression-free survival in unresectable hepatocellular carcinoma treated with the FOLFOX-HAIC regimen based on patient clinical characteristics and blood biomarkers
by: Qiuyao Zeng, et al.
Published: (2025-01-01)

Proteomic Characterization of Liver Cancer Cells Treated with Clinical Targeted Drugs for Hepatocellular Carcinoma
by: Hezhou Long, et al.
Published: (2025-01-01)

A New Risk Score Based on Lipid Indicators for Patients with Advanced Hepatocellular Carcinoma
by: Wei X, et al.
Published: (2025-01-01)

Lenvatinib and tislelizumab versus atezolizumab and bevacizumab in combination with TAE-HAIC for unresectable hepatocellular carcinoma with high tumor burden: a multicenter retrospective cohort study
by: Hongjie Cai, et al.
Published: (2025-02-01)

Deep learning based on multiparametric MRI predicts early recurrence in hepatocellular carcinoma patients with solitary tumors ≤5 cm
by: Tingting Mu, et al.
Published: (2024-12-01)

Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for unresectable HCC: a meta-analysis
by: Min Wei, et al.
Published: (2024-12-01)

Harnessing nanoparticles for reshaping tumor immune microenvironment of hepatocellular carcinoma
by: JinSong Li, et al.
Published: (2025-02-01)

Heterogeneity in polyamine metabolism dictates prognosis and immune checkpoint blockade response in hepatocellular carcinoma
by: Jianyan Pan, et al.
Published: (2025-02-01)

The histopathological and molecular heterogeneity of hepatocellular carcinoma: a narrative review
by: Wonju Chung, et al.
Published: (2024-10-01)

Unveiling etiology-specific blood biomarkers in hepatocellular carcinoma: A gateway to personalized medicine: Editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma”
by: Joseph C. Ahn, et al.
Published: (2024-10-01)

Effects of resveratrol-loaded dendrimer nanomedicine on hepatocellular carcinoma cells
by: Jiao Qu, et al.
Published: (2024-11-01)